IMCA-CAT is a synchrotron-based structural biology research facility

optimized for high-throughput macromolecular crystallography

serving the pharmaceutical drug discovery community.




The IMCA-CAT insertion device synchrotron beamline is designed with state-of-the-art equipment and is ideally suited for proprietary drug discovery research.

Intense focused beam, robotics for sample mounting, diffraction rastering and high-speed precision sample positioning, and shutterless continuous-rotation data collection enable the beamline to meet the throughput demands of the pharmaceutical industry.

Additional highlights of the beamline capabilities include wavelength tunability for MAD and SAD experiments, selectable mini beam for optimum beam size, and collect-along-a-vector for overcoming sample degradation.

Discovery and lead optimization phases of drug development both are accelerated with high-throughput data acquisition at IMCA-CAT.

Structural studies of the most challenging complexes, including membrane proteins, small crystals, and radiation-sensitive samples, benefit from advanced beamline capabilities.

Fragment screening high-throughput demands are met with fully automated and fast processes for data acquisition.

On-the-fly structural analyses are enabled by high-speed, secure, and encrypted data transfer for integrating with company-based pipelines.

Each year, more than 15,000 structures are solved from data collected at the IMCA-CAT synchrotron beamline.

Guaranteed, frequent, and routine access for proprietary data acquisition, whether on-site, remotely, or via mail-in, smoothly integrates with pharmaceutical drug design work flows.

The IMCA-CAT research facility is aimed at accelerating pharmaceutical drug discovery programs and performs to the highest standards of reliability, efficiency, and throughput.